Liver biopsy captures human proof of SERPINA1 correction in alpha-1 antitrypsin deficiency
A liver biopsy has delivered the most direct clinical evidence yet that in vivo base editing can precisely correct the pathogenic SERPINA1 variant driving alpha-1 antitrypsin deficiency (AATD). In a 66-year-old man with PI*ZZ disease, investigators obtained hepatic tissue 10 weeks after treatment and found correction of the disease-causing allele in more than half of measured alleles, with no evidence of hepatic inflammation and no detectable off-target signal in the tissue analyzed.
This is not a surrogate readout inferred from blood alone. It is a tissue-level look at the organ most burdened by the toxic misfolded protein that accumulates in AATD, and it brings the field closer to answering a central question in genetic liver disease: can editing machinery reach hepatocytes efficiently enough to rewrite the culprit sequence while leaving surrounding biology intact?
The answer, at least in this first clinical case, is encouraging.
What the biopsy showed after treatment
The patient had PI*ZZ AATD, the classic genotype linked to polymerization of the abnormal AAT-Z protein inside hepatocytes, reduced circulating alpha-1 antitrypsin, progressive liver injury, and pulmonary risk from deficient systemic protease inhibition. Before treatment, elastography had already identified F2 fibrosis, placing him in the window where liver-directed intervention still matters clinically.
Ten weeks after gene correction therapy within the YOLT-202 phase I/Ia trial, a liver biopsy was performed to evaluate both histology and editing performance. Histology did not show hepatic inflammation, an important safety observation in a setting where any new inflammatory activity could have clouded interpretation of the treatment effect or signaled injury from delivery or editing.
Sequencing told the main story. Sanger sequencing and Illumina sequencing both confirmed correction of the PI*ZZ variant, with 54% of alleles corrected by Sanger and 57% by Illumina. The analysis also looked for bystander changes and off-target editing, and none were detected in the biopsy material examined.
A single sentence captures the clinical weight of the finding: the target was edited, the liver remained quiet, and the unwanted genetic noise stayed absent in the sampled tissue.
Why hepatic correction matters in AATD
AATD has always posed a double problem. The liver is injured because hepatocytes produce a misfolded protein that they cannot process efficiently, while the lungs are deprived because circulating alpha-1 antitrypsin remains too low to counter neutrophil elastase. Any therapy that simply raises serum levels without addressing hepatic protein misfolding solves only part of the disease.
Base editing tackles the disorder at its source. By rewriting the mutant SERPINA1 sequence rather than adding an extra copy of the gene, the approach is designed to reduce production of the toxic AAT-Z protein while allowing physiologic protein expression to resume. In principle, that could lower the hepatocellular storage burden and restore biologically active AAT in the circulation at the same time. The present biopsy data support both halves of that therapeutic logic: hepatic editing occurred, and the corrected tissue was associated with sustained circulating AAT levels that retained biologic activity.
The biological mechanism is straightforward even if the technical execution is not. Once the mutant codon is repaired, hepatocytes should no longer be forced into the same cycle of misfolding, aggregation, and retention within the endoplasmic reticulum. Over time, that may reduce cellular stress and the fibrotic cascade that follows chronic injury. The actual clinical importance lies in whether enough hepatocytes are corrected to shift the organ’s behavior. This case suggests the editing fraction may be high enough to matter.
Serum alpha-1 antitrypsin remained biologically active
Liver tissue is only part of the story in AATD. The circulating protein must not only be present, but functional. Monthly follow-up showed sustained serum AAT levels after treatment, and the investigators assessed biological activity with an elastase inhibition assay. Activity was preserved throughout follow-up, which is the result clinicians care about when thinking beyond biomarker replacement and toward genuine protease protection in the lung.
A transient rise in transaminases occurred after treatment, then enzymes returned to baseline. In a first-in-human style setting, that pattern matters. Early enzyme elevation can reflect procedural or delivery-related stress, but normalization after the initial bump supports the view that the liver tolerated the intervention without ongoing biochemical injury in the observed period.
No one should mistake this for proof of long-term disease modification. The follow-up remains short, and a single biopsy cannot forecast what will happen over years of liver remodeling, fibrosis progression, or rare delayed toxicities. Even so, the combination of sustained biologically active AAT, absence of concerning histology, and molecularly confirmed correction makes this case unusually persuasive for a first report.
The clinical promise and the unanswered test
For hepatology, the significance lies in precision. Gene therapy programs often rely on indirect endpoints such as blood proteins, enzyme changes, or imaging markers. Here, the liver itself was sampled, and the tissue demonstrated on-target correction without a visible safety penalty in the examined specimen. That kind of confirmation is rare and especially valuable in monogenic liver disease, where the therapeutic goal is not palliation but sequence-level repair.
For patients with PI*ZZ AATD, the implication is equally concrete. A therapy that can substantially correct the pathogenic allele in hepatocytes, preserve liver histology, and sustain active circulating AAT could eventually alter both the hepatic and pulmonary dimensions of the disease. The current report does not establish that standard of care, but it does show the biological groundwork is achievable in a human liver.
The key unresolved issues are still substantial. The report describes one patient, one biopsy, and one early interval after treatment. Durability, reproducibility, dose-response behavior, broader safety, and the degree to which fibrosis can stabilize or regress after editing all remain open. Future trial readouts will need to show whether this molecular success can be repeated across a larger cohort and whether the edited liver maintains its correction over time without late toxicity.
Even so, the first tissue-level proof is difficult to ignore. In a disease defined by a broken gene and a stressed liver, the biopsy showed the gene had been corrected, the liver remained histologically quiet, and the corrected protein kept working.